While exhaustion markers, such as PD-1 and CTLA-4, remained stably expressed across tumor progression, co-stimulatory molecules, including CD28 and ICOS, were significantly downregulated by 6 weeks, highlighting a state of persistent checkpoint signaling coupled with a loss of co-stimulation (Fig. 5, Table 3). The gene discussed is PDCD1; the disease is neoplasm.